KLK3 and pachyonychia congenita: Screening of men in the Prostate Testing for Cancer and Treatment (ProtecT) trial have excluded 16% of men with high-risk disease (categorised as men identified with locally advanced (clinical stage T3–4) or metastatic (N1 or M1) PC, as well as those with PSA >20 ng/ml) [35, 36].